Newspaper Publication for Audited Financial results for Q and Year ended 31.03.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sandu Pharmaceuticals has published its audited financial results for Q4 FY25 and the full year ended March 31, 2025, originally approved by the Board on May 28, 2025, and now shared via newspaper publication as per SEBI LODR requirements. Consolidated total income for the quarter stood at ₹1,413.85 lakhs, down from ₹1,590.66 lakhs in Q4 FY24, while quarterly net profit after tax fell to ₹32.64 lakhs from ₹59.46 lakhs a year earlier. For the full year, total income was nearly flat at ₹6,735.99 lakhs (vs ₹6,770.43 lakhs in FY24), but net profit after tax rose to ₹155.17 lakhs (vs ₹146.12 lakhs). Full-year EPS improved to ₹1.60 from ₹1.51, indicating better profitability despite softer top-line growth.
Short-term, the Q4 profit dip of nearly 45% year-on-year may weigh on sentiment, but the full-year earnings growth and improved EPS suggest steady underlying performance. Shareholders should watch for management commentary on the Q4 slowdown in the detailed results.